Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab + BMS-813160 or BMS-986253 for NSCLC or HCC
NCT04123379Phase 2Active, not recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of BMS-813160, adakitug in non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), sponsored by Icahn School of Medicine at Mount Sinai. Started Mar 2020; status: active, not recruiting.
02
Drugs
BMS-813160adakitug
03
Conditions
non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04123379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123379.